Ex­clu­sive: Shi­no­bi rais­es $51M to take on cell ther­a­py chal­lenges with ex-Wu­gen CEO at helm, Carl June in sup­port

Last year
Financing
Startups

Pfiz­er to com­plete Seagen ac­qui­si­tion Thurs­day, An­gela Hwang to de­part amid ex­ec­u­tive shuf­fle

Last year
Deals
Pharma

Bris­tol My­ers bags Sys­tIm­mune’s lung can­cer drug for $800M up­front in its third ADC-fo­cused pact of 2023

Last year
Deals
R&D

Ex­clu­sive: Women’s health biotech Freya Bio­sciences rais­es $38M for mi­cro­bial im­munother­a­pies

Last year
Financing
Startups

Bio­con on­col­o­gy spin­out Bicara se­cures its sec­ond nine-fig­ure fi­nanc­ing of the year

Last year
Financing
Startups

As­traZeneca plunks down $800M+ up­front to buy vac­cine de­vel­op­er Icosavax and chal­lenge Pfiz­er, GSK in RSV

Last year
Deals

Biotech CAR-T roundup: Au­to­lus, Gra­cell tout ear­ly-stage da­ta at #ASH23

Last year
R&D
Cell/Gene Tx

Bris­tol My­ers and 2sev­en­ty bio's Abec­ma sur­vival da­ta raise ques­tions ahead of FDA’s ad­vi­so­ry com­mit­tee meet­ing: ...

Last year
R&D

FTC ex­pands phar­ma scruti­ny to ear­ly-stage deals, forc­ing Sanofi to drop Pompe dis­ease part­ner­ship with Maze

Last year
Deals

Fer­ring Phar­ma­ceu­ti­cals lays off 134 em­ploy­ees be­tween NJ and MN lo­ca­tions

Last year
People
Pharma

Bi­par­ti­san House bill seeks to boost pe­di­atric drug de­vel­op­ment via new FDA penal­ties for non­com­pli­ance

Last year
R&D
Pharma

J&J ac­cused of de­fraud­ing US Patent Of­fice in an­ti-com­pe­ti­tion law­suit

Last year
Pharma
Law

Af­ter two his­toric ap­provals, Ed­i­tas un­veils promis­ing ear­ly re­sults for its sick­le cell ther­a­py: #ASH23

Last year
R&D

Graphite founder takes drug to re­cent­ly-launched Ka­mau Ther­a­peu­tics for a sec­ond chance: #ASH23

Last year
Startups
Cell/Gene Tx

Catal­ent de­tails rev­enue down­turn, staff cuts as it looks for­ward to a brighter 2024

Last year
Manufacturing

Af­fimed nar­rows PhI/IIa fo­cus; Bris­tol My­ers pays Agenus $25M; Mer­ck, Mod­er­na start an­oth­er PhI­II can­cer vac­cine

Last year
News Briefing

Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel ...

Last year
People
R&D

ICER un­veils lat­est re­port on 'un­sup­port­ed' drug price in­creas­es

Last year
Pharma
FDA+

Ho­ba, a Dan­ish biotech from No­vo, rais­es $25M to crack in­to dif­fi­cult pain and hear­ing loss fields

Last year
Financing
Startups

Cigna’s merg­er talks with Hu­mana have re­port­ed­ly fall­en through

Last year
Health Tech

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

Last year
R&D
Cell/Gene Tx

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

Last year
R&D
Cell/Gene Tx

Ar­cel­lx, Kite aim to keep chip­ping away at Carvyk­ti ad­van­tage with new mul­ti­ple myelo­ma da­ta: #ASH23

Last year
R&D
Cell/Gene Tx

Cor­rect­ed: BeiGene builds out long-term case for Brukin­sa in CLL with three-year fol­low-up da­ta

Last year
R&D
Pharma
First page Previous page 232233234235236237238 Next page Last page
A service from the Financial Times